CD274 and non-small cell lung carcinoma: The US FDA has granted approval for three PD-L1 inhibitors, namely Atezolizumab, Durvalumab, and Avelumab, which have been used to treat some solid tumors, including NSCLC, HNSCC, melanoma, and MCC [116].